Essential data for developing bacteriophage therapeutics
1
조회
0
다운로드
0
인용
0
참고문헌
초록
The rise of multidrug-resistant organisms is a significant global health threat, projected to cause up to 10 million deaths annually by 2050, surpassing cancer as the leading cause of mortality [1]. Traditional antibiotic development has not kept pace with this threat, necessitating innovative approaches to combat resistant pathogens. Bacteriophage therapy, which leverages viruses to specifically target and destroy bacteria, has emerged as a promising alternative. This letter outlines the key developments in bacteriophage research, the challenges facing its clinical application, and the steps necessary to integrate phage therapy into mainstream medical practice
Abstract
The rise of multidrug-resistant organisms is a significant global health threat, projected to cause up to 10 million deaths annually by 2050, surpassing cancer as the leading cause of mortality [1]. Traditional antibiotic development has not kept pace with this threat, necessitating innovative approaches to combat resistant pathogens. Bacteriophage therapy, which leverages viruses to specifically target and destroy bacteria, has emerged as a promising alternative. This letter outlines the key developments in bacteriophage research, the challenges facing its clinical application, and the steps necessary to integrate phage therapy into mainstream medical practice
참고문헌 (14)
- "Tackling drug-resistant infections globally: final report and recommendations" (2016)[URL]
- Jędrusiak A, "Phage interactions with the nervous system in health and disease", Cells, 12, pp.1720~ (2023)
- Dedrick RM, "Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus", Nat Med, 25, pp.730~733 (2019)
- Schooley RT, "Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection", Antimicrob Agents Chemother, 61, pp.10~1128 (2017)
- Suh GA, "Considerations for the use of phage therapy in clinical practice", Antimicrob Agents Chemother, 66, pp.e02071~21 (2022)
- Łusiak-Szelachowska M, "Cater K, Knežević P, Winogradow C, et al. Bacteriophages and antibiotic interactions in clinical practice : what we have learned so far", J Biomed Sci, 29, pp.23~ (2022)
- Chae D, "Phage-host-immune system dynamics in bacteriophage therapy : basic principles and mathematical models", Transl Clin Pharmacol, 31, pp.167~190 (2023)
- Aslam S, "Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrugresistant bacterial infections at a single center in the United States", Open Forum Infect Dis, 27, pp.ofaa389~ (2020)
- Jault P, "Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa(PhagoBurn) : a randomised, controlled, double-blind phase 1", 2 trial, 2019, pp.19, 35~45
- Suh GA, "Phage therapy as a novel therapeutic for the treatment of bone and joint infections", Clin Infect Dis, 77(Suppl 5), pp.S407~15 (2023)
- Furfaro LL, "Bacteriophage therapy : clinical trials and regulatory hurdles", Front Cell Infect Microbiol, 8, pp.376~ (2018)
- Pires DP, "Current challenges and future opportunities of phage therapy", FEMS Microbiol Rev, 44, pp.684~700 (2020)
- Fabijan AP, "Translating phage therapy into the clinic : recent accomplishments but continuing challenges", PLoS Biol, 21, pp.e3002119~ (2023)
- Karn SL, "Phage therapy : a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens", Front Med, 10, pp.1209782~ (2023)